MK-7075 (Miransertib) in Proteus Syndrome

NCT04316546 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

NIH

Sponsor class

Conditions

Proteus Syndrome

Interventions

DRUG: MK-7075 (miransertib)

Sponsor

National Human Genome Research Institute (NHGRI)